Skip to content

Remimazolam and flumazenil for Rapid Sequence Awakeness method in pediatric anesthesia

A study of the Rapid Sequence Awakeness method by reversing remimazolam with flumazenil in pediatric anesthesia, A randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs021240059
Enrollment
108
Registered
2025-02-06
Start date
2025-02-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases for which scheduled surgery is performed under general anesthesia

Interventions

Awake group: Maintain anesthesia with sevoflurane, and extubate after confirming the patient's awakening. RSA group: Switch from sevoflurane to remimazolam as maintenance drug before the end of surger

Sponsors

Yakushiji Tatsumi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients scheduled for surgery under general anesthesia who meet the following criteria. 1) Patients 1-6 years of age at the time of consent. 2) Patients with an American Society of Anesthesiologists physical status (ASA-PS) of 1-2 at the preoperative visit. 3) Patients scheduled to have their airway secured by oral tracheal intubation. 4) Patients scheduled for extubation in the operating room. 5) Patients who have been fully informed about the study and have provided written informed consent from a surrogate.

Exclusion criteria

Exclusion criteria: 1) Patients scheduled to undergo craniotomy 2) Patients whose scheduled operation time is less than 20 minutes but longer than 4 hours 3) Patients who are expected to bleed heavily (more than 15% of circulating blood volume) during surgery 4) Patients who are expected to have difficulty with mask ventilation, intubation, but extubation 5) At risk of vomiting or aspiration during the perioperative period 6) Patients with a history of severe allergy to benzodiazepines, flumazenil citrate, remifentanil hydrochloride, fentanyl citrate, rocuronium bromide, or sugammadex sodium 7) Patients who have been taking benzodiazepines regularly before surgery or have a history of tolerance to benzodiazepines 8) Patients with a history of epilepsy 9) Patients with a history of glaucoma 10) Other patients deemed inappropriate by the principal investigator or subinvestigator

Design outcomes

Primary

MeasureTime frame
Incidence of EA/ED up to 15 minutes after awakening and extubating

Secondary

MeasureTime frame
PAEDs score on admission to the PICU and at each time point (*) after admission to the PICU Percentage of EAs/EDs on admission to the PICU and at each time point (*) after admission to the PICU Percentage of PRAEs in the operating room Percentage of PRAEs occurring up to 2 hours after PICU admission Percentage of cases requiring airway/respiratory intervention within 2 hours of PICU admission Percentage of resuscitations within 2 hours of PICU admission Time from end of surgical procedure to patient leaving the operating room FLACCs score after extubation FLACCs score on admission to PICU and at each assessment time point (*) Subjective assessment by anesthesiologist of quality of emergence and extubation from general anesthesia. *Evaluation time points are defined as at the time of admission to the PICU + 10 minutes and 30 minutes +/- 10 minutes, 60 minutes +/- 10 minutes, and 120 minutes +/- 10 minutes after admission to the PICU.

Contacts

Public ContactTatsumi Yakushji

Fukushima Medical University Hospital

masui@fmu.ac.jp+81-24-547-1342

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026